Sun Pharmaceuticals rating – Buy- One-offs hit bottomline in Q4FY22
时间:2024-06-26 11:36:01 阅读(143)
Sun reported net loss of Rs 22.8 bn in Q4, mainly on one-offs of Rs 39.4 bn (Rs 37.2 bn of provisions related to settlement of antitrust litigation for valganciclovir, valsartan and esomeprazole, Rs 1.6 bn of provisions for settlement with various purchaser groups and Rs 563.5 m for restructuring of certain businesses). It also booked a one-off tax gain of Rs 764.2 m and FX gain of Rs 1.6 bn. Adjusting for one-offs and FX, PAT was Rs 14.2 bn (~19% below HSBCe). EBITDA margins at 23.1% fell 109bps y-o-y and 346bps q-o-q on input cost pressure and normalisation of expenses.
Traction continues for specialty sales: Global sales for the specialty products portfolio of $185 m grew ~33% y-o-y (+1% q-o-q) on strong traction in key brands Ilumya, Cequa, and Odomzo. Specialty sales in FY22 grew 42% to $673 m (13% of total revenues vs 7% in FY18). Global sales for Ilumya (incl. milestones and royalties) reached $315 m (+81% y-o-y). Winlevi (novel acne drug launched in Nov 2021) is seeing good traction and around 9K prescribing doctors (out of 15K) have prescribed it. We expect sales traction to continue for key brands on improving patient footfall (elective procedures are not yet back to pre-COVID-19 levels), better commercial execution and increasing market size.
Retain Buy rating: We remain positive on Sun’s efforts in the specialty products portfolio, which we believe will likely achieve Ebitda breakeven over the next 2-3 years, resulting in significant operating leverage. We assume specialty sales to be key driver of US sales, with sales CAGR of 17.2% for FY22-25e, while we assume base generic and Taro sales stabilising at current levels.
Sun plans to expand India sales headcount by 10% in FY23e to improve market coverage and de-clutter some marketing divisions. We assume its India segment sustaining above-market growth on new launches and better reach. The outlook remains largely steady for other segments (RoW, emerging markets, API, etc.) barring any short-term fluctuations. Post Q4, we adjust our estimates per current visibility leading to 3.3%/3.5% cuts in EPS for FY23/24e. Our TP is Rs 1,040 (from Rs 1,075).
上一篇:Zee’s Punit Goenka pays Rs 50 lakh to settle insider trading case
下一篇:Your queries- Loans; Brother-sister duo is not automatically given loan
猜你喜欢
- Share Market Highlights- Nifty settles above 18000, Sensex gains 240 pts; Bank Nifty rises 80 pts, IT ends over 1% up
- Medanta- Growth momentum to continue; projects CAGR of 14%, 17% in Ebitda & 26% in PAT from FY23-FY25
- Mazagon Dock, JK Lakshmi Cement among 149 BSE stocks to hit 52-week highs, 19 fall to 52-week lows
- SGX Nifty tanks, Nifty technical view, Q4 results, derivatives data, US Fed comments; key things to watch out
- Yes Bank shares rally 20% over two sessions; here’s why the stock is surging in trade
- Share Market Highlights- Nifty, Sensex end flat, NSE index below 18600; Bank Nifty above 44150, Auto, Realty gain, IT tanks
- Will the strong GDP numbers propel Nifty to claim a new high- 8 things to know before the share market opens
- Yes Bank shares drops over 2 per cent after June quarter earnings
- Year ahead generative AI - Focus will now shift to inference